Register for your FREE account now and join the thousands of healthcare professionals who have depended on us for over 26 years for accurate, concise, and timely drug information.

Keep me logged in Forgot your password?

Please wait...

Please wait...

Dermatological Disorders Resource Center

Welcome to the MPR Dermatological Disorders Resource Center, where you will find everything you need to make informed clinical decisions.

News

Epidemiology of Rosacea Described in United Kingdom

The incidence of rosacea in the United Kingdom is 1.65 per 1,000 person-years, with alcohol consumption linked to a modest increase in risk and current smoking linked to an decreased risk.
 

Fabior Foam, 0.1% Approved for Acne Vulgaris

Stiefel has received FDA approval for Fabior Foam, 0.1%, for the treatment of acne vulgaris in patients 12 years of age and older.
 

Sun Protective Behavior on the Rise in US Adults

Adults in the United States may be taking more precautions to avoid sunburn outdoors, but many are still getting burned, and a substantial proportion are utilizing indoor tanning.
 

Sun/Skin Cancer Counseling Recommended for Youth

The US Preventive Services Task Force (USPSTF) recommends that physicians counsel children, adolescents, and young adults who have fair skin about ultraviolet radiation exposure and skin cancer prevention.
 

Women Have Clear Melanoma Survival Advantage Over Men

Women with localized melanoma have a consistent advantage over men of approximately 30% for survival and progression.
 

New Drugs

PICATO

3/5/2012

LEO Pharma Inc.
Active Ingredient(s): Ingenol mebutate 0.015%, 0.05%; topical gel.
Indication: Topical treatment of actinic keratosis (AK).
 

NATROBA

10/6/2011

ParaPRO
Pharmacological Class: Pediculicide.
Active Ingredient(s): Spinosad 0.9%; topical ­suspension; contains benzyl alcohol.
Indication: Head lice.
 

YERVOY

4/28/2011

Bristol-Myers Squibb
Pharmacological Class: Cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody.
Active Ingredient(s): Ipilimumab 5mg/mL; soln for IV infusion; preservative-free.
Indication: Treatment of unresectable or ­metastatic melanoma.
 

Toolbox

Psoriasis: New Thoughts and New Horizons: A Focus on Therapy

1.00/ AMA PRA Category 1 Credit(s)TM
 

New Drug Review from MPR (May 2012)

0.75/ AMA PRA Category 1 Credit(s)TM
0.75/ CE for Pharmacists
 

ClinicalJobAdvisor

Loading...

More Jobs

© 2012 Haymarket Media, Inc.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions